Amarin (AMRN)
(Delayed Data from NSDQ)
$0.67 USD
-0.03 (-4.51%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $0.68 +0.01 (1.04%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
Brokerage Reports
Amarin Corporation PLC [AMRN]
Reports for Purchase
Showing records 161 - 180 ( 359 total )
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Upon Closer Look, What Does EVAPORATE Tell Us?
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Cost-effectiveness Results Add Another Notch to the Belt
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Let''s Decode the AdCom to Figure Out Label Possibilities
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Get a Head Start on AHA in Philadelphia with Our Prep Material
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Putting Numbers Behind Yesterday?s Positive AdCom Vote
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
FDA AdCom Focus on Safety and Placebo Effects Suggest Satisfactory Efficacy, in Our View
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Briefing Book Charts a Favorable Path Forward to AdCom Vote
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Healthcare - Earnings Recap: Halftime Show of Our Most In-Depth, Differentiated Earnings Yet
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
With FDA AdCom in Sight, We Identify EMDAC Trends Supportive of Vascepa Progress.
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
3Q19 - All of the Hot Topics for AdCom Reviewed in Our Report
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y